DE3580607D1 - Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum. - Google Patents

Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum.

Info

Publication number
DE3580607D1
DE3580607D1 DE8585400784T DE3580607T DE3580607D1 DE 3580607 D1 DE3580607 D1 DE 3580607D1 DE 8585400784 T DE8585400784 T DE 8585400784T DE 3580607 T DE3580607 T DE 3580607T DE 3580607 D1 DE3580607 D1 DE 3580607D1
Authority
DE
Germany
Prior art keywords
inhibitoric
materialized
tumor growth
against tumor
factor against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585400784T
Other languages
English (en)
Inventor
George J Todaro
Charlotte A Fryling
Kenneth K Iwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Application granted granted Critical
Publication of DE3580607D1 publication Critical patent/DE3580607D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE8585400784T 1984-04-20 1985-04-19 Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum. Expired - Fee Related DE3580607D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/602,520 US4708948A (en) 1984-04-20 1984-04-20 Substantially purified tumor growth inhibitory factor

Publications (1)

Publication Number Publication Date
DE3580607D1 true DE3580607D1 (de) 1991-01-03

Family

ID=24411683

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585400784T Expired - Fee Related DE3580607D1 (de) 1984-04-20 1985-04-19 Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum.

Country Status (5)

Country Link
US (1) US4708948A (de)
EP (1) EP0159276B1 (de)
JP (2) JP2550307B2 (de)
CA (1) CA1311704C (de)
DE (1) DE3580607D1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4849506A (en) * 1984-04-13 1989-07-18 Akzo N.V. Leukoregulin, an antitumor lymphokine, and its therapeutic uses
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US6586394B1 (en) 1985-04-19 2003-07-01 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitor
US6559123B1 (en) * 1985-04-19 2003-05-06 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
ES2065318T3 (es) * 1986-07-15 1995-02-16 Kowa Co Sustancia que se une a trombina y procedimiento para su preparacion.
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
US5196334A (en) * 1988-09-02 1993-03-23 Baylor College Of Medicine Urogenital sinus derived growth inhibitory factor
US4983699A (en) * 1989-01-03 1991-01-08 Ppg Industries, Inc. Silylated addition polymers with pendant ionic moieties
DE3907822A1 (de) * 1989-03-10 1990-09-13 Adolf Dr Loefflmann Verwendung einer peroxidaseaktivitaet zeigenden proteinfraktion aus dem photosyntheseapparat von pflanzen als arzneimittel, insbesondere zur krebsbekaempfung, sowie verfahren zur gewinnung einer proteinmischung und arzneimittel zur krebsbekaempfung
JP2784272B2 (ja) * 1990-06-06 1998-08-06 大正製薬株式会社 腫瘍細胞増殖阻害因子
CA2084992A1 (en) * 1990-06-25 1991-12-26 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof
US5242692A (en) * 1990-07-10 1993-09-07 Bar Ilan University Anti-metastatic factor
US5648340A (en) * 1991-10-31 1997-07-15 Barnea; Eytan R. Gestational agents for controlling cell proliferation
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
WO1993024627A1 (en) * 1992-06-03 1993-12-09 Case Western Reserve University Bandage for continuous application of biologicals
EP0821969B1 (de) 1992-07-16 2006-11-22 Daiichi Pharmaceutical Co., Ltd. Arzneimittelzusammensetzung enthaltend TCF-II
IL111021A0 (en) * 1994-09-22 1994-11-28 Mor Research Applic Ltd Factor derived from muscle cells
WO1996013586A2 (en) * 1994-10-26 1996-05-09 Nobuko Satomi Histiocyte-secreted factor (hsf)
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6864066B1 (en) 1999-09-08 2005-03-08 The Regents Of The University Of California Epithelial protein lost in neoplasm (EPLIN)
AU7361000A (en) * 1999-09-08 2001-04-10 Regents Of The University Of California, The Epithelial protein lost in neoplasm (eplin)
CN101058809B (zh) * 2007-04-02 2010-09-08 苏州大学 人源化改造的鼠ing4基因及其腺病毒表达载体在制备治疗肺癌的药物中的应用
JP7002364B2 (ja) 2018-03-01 2022-01-20 三桜工業株式会社 曲げ成形型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261976A (en) * 1978-10-03 1981-04-14 The Massachusetts General Hospital Method and glycoprotein composition for inhibition of growth of transformed cells and tumors
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin

Also Published As

Publication number Publication date
EP0159276A2 (de) 1985-10-23
JP2702103B2 (ja) 1998-01-21
EP0159276B1 (de) 1990-11-22
JPH08231593A (ja) 1996-09-10
EP0159276A3 (en) 1986-07-30
US4708948A (en) 1987-11-24
JPS6133120A (ja) 1986-02-17
JP2550307B2 (ja) 1996-11-06
CA1311704C (en) 1992-12-22

Similar Documents

Publication Publication Date Title
DE3580607D1 (de) Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum.
DK433485D0 (da) Vaeksthormonfrigivende faktor
NO885339D0 (no) Leukemi-inhiberende faktor.
FI851497A0 (fi) Framstaellning av maenskans funktional faktor viii.
FI845177A0 (fi) Intraokulaer lins.
NO872261D0 (no) Belegningsmateriale.
DE3581528D1 (de) Insulinaehnlicher wachstumsfaktor ii.
DE69022084D1 (de) Herzschrittmacherleiter.
DK108685A (da) Vaekstfaktor i
NO852545L (no) Konvertabel vertikal sjakt-stoet-steinknuser.
DK601885D0 (da) Paafaestningsorgan
NO860666L (no) Dekorative belegg.
FI880020A0 (fi) Vaesentigen ren cytotoxitet utloesande faktor.
DE3584005D1 (de) Im gehirn entstehender wachstumsfaktor.
NO862245D0 (no) Antibegroningsmaling.
FI885055A (fi) Celltillvaext inhiberande faktor.
FI893474A (fi) Neutrofiler aktiverande faktor.
NO865178L (no) Cellevekstregulerende faktor.
NO161592C (no) Blomsterpotte.
FI842488A0 (fi) Foerfarande foer styrning av sulfitkokningar och hydrolytiska processer medelst en snabb furfuralanalysator.
DE3688239D1 (de) Hemmungsmittel des partikelwachstums.
FI855008A (fi) Polymera foertjockningsmedel foer hydraulikvaetskor i vaetskeform.
NO872994D0 (no) Belegningsmateriale.
FI863757A (fi) Human granulosytkolonistimulerande faktor.
FI850196L (fi) Tillslutare av plast foer medicinglas o.d.behaollare.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee